Avelox: Treatment for Antibiotic Resistant Infections

During the colder winter season, many people begin to suffer from more common cases of upper respiratory infections and sinusitis. This is especially true for adults who care for children exposed to infections in the school environment. For these active adults, finding a powerful antibiotic, to fight infection, is the primary medical focus while ensuring the health does not deteriorate further. When dealing an antibiotic resistant upper respiratory infection of case of sinusitis, discuss the use of Avelox, in the fight against bacterial infections, especially in severe resistant cases.

Avelox, manufactured by Bayer, lends its success as an antibiotic which possesses the properties so desperately needed to find the most difficult of infections. Most commonly, Avelox is used in the treatment of antibiotic resistance bacteria associated with upper respiratory infections, sinusitis, and bronchitis.

Dosing of Avelox, in the treatment of upper respiratory infections, is generally achieved through a capsule form, once per day, at 400 milligrams. The duration of Avelox administration will vary depending on the type and severity of the bacterial infection. Fortunately, medical research has indicated that, in some forms of bacterial treatment, the use of Avelox at other dosing levels may provide the same lasting benefits as that of a standard 400 milligram dose. As a result, when considering the use of Avelox, in the treatment of an antibiotic resistant infection, the dosing recommendation should remain consistent at 400 milligrams per day.